1,247 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
AGN Allergan plc. $184.29 $62.56B Buy
Article Searches
Aurinia's Mid-Stage Results: More Than Meets The Eye https://seekingalpha.com/article/4234970-aurinias-mid-stage-results-meets-eye?source=feed_sector_healthcare Jan 23, 2019 - Aurinia Pharmaceuticals' voclosporin ophthalmic solution comes in line with safety in head to head study with Restasis for dry eye disease but beats it on two efficacy secondary endpoints.Voclosporin
AXS-05 Data Could Benefit MDD Patients While Leaving Axsome Shareholders Aching https://seekingalpha.com/article/4233275-axsminus-05-data-benefit-mdd-patients-leaving-axsome-shareholders-aching?source=feed_all_articles Jan 22, 2019 -
Bernard Horn's Polaris Global Value Fund 4th Quarter Commentary http://www.gurufocus.com/news/803110/bernard-horns-polaris-global-value-fund-4th-quarter-commentary Jan 21, 2019 - Bernard Horn's Polaris Global Value Fund 4th Quarter Commentary, Stocks: ABCB,MEOH,LXS,AGN,TEVA,, Bernard Horn, release date:Jan 21, 2019
Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C http://www.zacks.com/stock/news/347742/ironwoods-irwd-linzess-gets-approval-in-china-for-ibs-c?cid=CS-ZC-FT-347742 Jan 16, 2019 - Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C
Aurinia Offers A Lot Of Upside Potential With Upcoming Phase 2 Dry Eye Disease Study Readout https://seekingalpha.com/article/4233601-aurinia-offers-lot-upside-potential-upcoming-phase-2-dry-eye-disease-study-readout?source=feed_sector_healthcare Jan 15, 2019 - Aurinia Pharmaceuticals is expected to release results from its phase 2 dry eye disease study any day now in January of 2019.The global dry eye disease market is expected to reach $7.7 billion by 2025
Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet http://www.zacks.com/stock/news/347005/pharma-stock-roundup-lilly-to-buy-loxo-for-%248b-ma-in-focus-at-jp-morgan-meet?cid=CS-ZC-FT-347005 Jan 11, 2019 - Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff http://www.zacks.com/stock/news/346023/ironwood-to-get-new-ceo-current-ceo-to-head-latest-spinoff?cid=CS-ZC-FT-346023 Jan 07, 2019 - Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Merck Doesn't Want To Be Left Out Of The NASH Race Either, Uses Option Agreement https://seekingalpha.com/article/4231541-merck-want-left-nash-race-either-uses-option-agreement?source=feed_sector_healthcare Jan 04, 2019 - Merck takes option to license NGM313 drug for NASH, which will be used in a phase 2 study known under a different name as MRK-3655.The main deal between Merck & NGM Bio was $450 million to develop bio
Why Allergan (AGN) Could Beat Earnings Estimates Again http://www.zacks.com/stock/news/345813/why-allergan-agn-could-beat-earnings-estimates-again?cid=CS-ZC-FT-345813 Jan 04, 2019 - Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
End Of The Line For Synergy Pharmaceuticals https://seekingalpha.com/article/4229299-end-line-synergy-pharmaceuticals?source=feed_sector_healthcare Dec 19, 2018 - Synergy filed for bankruptcy after failing to amend the liquidity and revenue covenants of its loan facility with private lender CRG.Bausch Health has offered $200 million for its assets; other bids m

Pages: 123456...125

Page 1>

Related Companies

Name Exchange Price Mkt Cap
CELG Celgene Corporation NASDAQ $87.23 $61.35B
SHPG Shire plc NASDAQ $176.25 $46.08B
VRTX Vertex Pharmaceuticals Incorporated NASDAQ $175.8 $44.93B
ZTS Zoetis Inc. NYSE $88.3 $42.55B
REGN Regeneron Pharmaceuticals, Inc. NASDAQ $386.665 $41.78B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Allergan plc.
AGN - Google Finance https://www.google.com/finance?q=AGN Industry related info and international coverage Summary News
AGN - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=AGN Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options